Katsunobu Hagihara - Concepedia

Author

Katsunobu Hagihara

Daiichi-Sankyo (Japan)ORCID

Also Known As

K Hagihara, K. HAGIHARA, K. Hagihara, Katsunobu Hagihara, Ping Zhang

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Daiichi-Sankyo (Japan)Eli Lilly (United States)Daiichi Sankyo (Germany)Yokohama University of Pharmacy University of California, San Francisco

About

Katsunobu Hagihara is an author at Daiichi-Sankyo (Japan) specializing in medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	464
2	Natural Sciences	2	2	23
3	Allergy	2	2	44
4	Biochemistry	2	2	230
5	Allergy Medicine	1	1	33

Katsunobu Hagihara

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Clinical Cancer Research	2016	1K
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite Miho Kazui, Yumi Nishiya, Tomoko Ishizuka, Drug Metabolism and Disposition	2009	808
Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, Cancer Science	2016	660
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara, Journal of Thrombosis and Haemostasis Molecular PharmacologyThrombosisEfficient GenerationBiochemistryBlood Platelet	2007	218
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade Chien-Chun Steven Pai, John Huang, Xiaoqing Lu, Immunity Tumor-specific T CellsTumor ImmunologyCancer ImmunosurveillanceClonal DeletionImmunology	2019	134
A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel Katsunobu Hagihara, Miho Kazui, Atsushi Kurihara, Drug Metabolism and Disposition	2009	121
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice Hiromi Okamoto, Masataka Oitate, Katsunobu Hagihara, Xenobiotica	2020	75
Comparison of Human Cytochrome P450 Inhibition by the Thienopyridines Prasugrel, Clopidogrel, and Ticlopidine Katsunobu Hagihara, Yumi Nishiya, Atsushi Kurihara, Drug Metabolism and Pharmacokinetics	2008	73
Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel Yumi Nishiya, Katsunobu Hagihara, Atsushi Kurihara, Xenobiotica	2009	63
Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel Yumi Nishiya, Katsunobu Hagihara, Takashi Ito, Drug Metabolism and Disposition	2008	62

Page 1